CA2458798C - Method for reducing hypertension and heart failure - Google Patents

Method for reducing hypertension and heart failure Download PDF

Info

Publication number
CA2458798C
CA2458798C CA2458798A CA2458798A CA2458798C CA 2458798 C CA2458798 C CA 2458798C CA 2458798 A CA2458798 A CA 2458798A CA 2458798 A CA2458798 A CA 2458798A CA 2458798 C CA2458798 C CA 2458798C
Authority
CA
Canada
Prior art keywords
mammal
set forth
tyrphostin
heart failure
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2458798A
Other languages
English (en)
French (fr)
Other versions
CA2458798A1 (en
Inventor
Mohammed A. Q. Siddiqui
Eduardo Mascareno
Daniel L. Beckles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CA2458798A1 publication Critical patent/CA2458798A1/en
Application granted granted Critical
Publication of CA2458798C publication Critical patent/CA2458798C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2458798A 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure Expired - Fee Related CA2458798C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/945,192 2001-08-31
US09/945,192 US6433018B1 (en) 2001-08-31 2001-08-31 Method for reducing hypertrophy and ischemia
PCT/US2002/023444 WO2003020202A2 (en) 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure

Publications (2)

Publication Number Publication Date
CA2458798A1 CA2458798A1 (en) 2003-03-13
CA2458798C true CA2458798C (en) 2013-06-25

Family

ID=25482762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2458798A Expired - Fee Related CA2458798C (en) 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure

Country Status (11)

Country Link
US (2) US6433018B1 (OSRAM)
EP (1) EP1427401A4 (OSRAM)
JP (2) JP2005505545A (OSRAM)
KR (1) KR20040050894A (OSRAM)
AU (1) AU2002313700B2 (OSRAM)
BR (1) BR0212252A (OSRAM)
CA (1) CA2458798C (OSRAM)
MX (1) MXPA04001913A (OSRAM)
NZ (1) NZ531693A (OSRAM)
WO (1) WO2003020202A2 (OSRAM)
ZA (1) ZA200402540B (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20050038450A1 (en) * 2003-06-03 2005-02-17 Ping Hu Methods and apparatus for minimally invasive transverse aortic banding
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US20050130893A1 (en) * 2003-09-30 2005-06-16 Joan Smith-Sonneborn Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure
PT1701941E (pt) 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US8691877B2 (en) * 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
EP1904457B1 (en) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
ES2506040T3 (es) 2005-11-16 2014-10-13 Cti Biopharma Corp. Derivados de pirimidina ligados a oxígeno
CA2637044A1 (en) * 2006-01-13 2007-07-26 President And Fellows Of Harvard College Xenohormesis based compositions and methods
JP2009528295A (ja) * 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US8410173B2 (en) * 2006-02-28 2013-04-02 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
PL2514742T3 (pl) * 2006-03-31 2015-07-31 Univ Texas Leki przeciwnowotworowe będące pochodnymi kwasu kawowego dostępnymi biologicznie po podaniu doustnym
US8486941B2 (en) 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
US8138339B2 (en) * 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
JP5675606B2 (ja) 2008-07-08 2015-02-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム シグナル伝達性転写因子（ｓｔａｔ）の増殖及び活性化の新規の抑制剤
SG171907A1 (en) 2008-12-11 2011-07-28 S Bio Pte Ltd 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
CA2768543C (en) * 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5275966B2 (ja) * 2009-12-21 2013-08-28 パナソニック株式会社 繊維ボードの製造方法
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2012634A1 (en) * 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US6255296B1 (en) 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US6358954B1 (en) * 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE602006000402T8 (de) * 2006-06-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Stabile Zubereitung enthaltend eine feuchtigkeitsempfindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung.

Also Published As

Publication number Publication date
CA2458798A1 (en) 2003-03-13
ZA200402540B (en) 2005-06-29
US6433018B1 (en) 2002-08-13
BR0212252A (pt) 2004-09-14
WO2003020202A3 (en) 2003-08-28
NZ531693A (en) 2006-05-26
EP1427401A2 (en) 2004-06-16
JP2005505545A (ja) 2005-02-24
AU2002313700B2 (en) 2007-04-26
JP2010285455A (ja) 2010-12-24
MXPA04001913A (es) 2004-06-18
WO2003020202A2 (en) 2003-03-13
US7235588B2 (en) 2007-06-26
EP1427401A4 (en) 2009-04-29
KR20040050894A (ko) 2004-06-17
US20040266661A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
AU2002313700B2 (en) Method for reducing hypertension and heart failure
AU2002313700A1 (en) Method for reducing hypertension and heart failure
Grocott-Mason et al. Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide
Dell'italia et al. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs
Lawrie et al. Paigen diet–fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1–dependent manner
Bulhak et al. Protection against myocardial ischaemia/reperfusion injury by PPAR–α activation is related to production of nitric oxide and endothelin–1
JP2010001311A (ja) 心肥大のための処置としてのヒストンデアセチラーゼの阻害
Li et al. Silencing salusin β ameliorates heart failure in aged spontaneously hypertensive rats by ROS-relative MAPK/NF-κB pathways in the paraventricular nucleus
US11213514B2 (en) Alpha-1-adrenergic receptor agonist therapy
KR20010031179A (ko) 레닌-안지오텐신 시스템 억제제의 용도
US20070167386A1 (en) Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same
JP7193874B2 (ja) 筋肉Ａキナーゼアンカータンパク質（ｍＡＫＡＰ）作用の阻害による心臓病の処置
Shi et al. The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger
Ren et al. Salidroside treatment decreases the susceptibility of atrial fibrillation in diabetic mice by reducing mTOR-STAT3-MCP-1 signaling and atrial inflammation
EP2882431A1 (en) Probenecid for treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure
WO2021073249A1 (zh) β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用
CN103429242A (zh) 用于预防和治疗心脏肥大的方法和组合物
US20120288486A1 (en) Method for Ameliorating or Preventing Arrhythmic Risk Associated with Cardiomyopathy
CN108430517A (zh) 利用fgf12的血管平滑肌细胞增殖性疾病的诊断、预防或治疗用组合物
US20120276012A1 (en) Method of Treatment and Screening Method
Robillard et al. Apelin improves angiogenesis and blood flow reperfusion following lower limb ischemia in diabetic mice
JP2003531114A (ja) プロテインキナーゼα阻害剤の使用
Karsentya et al. SESSION PL ENIERE: METABOLISMES, DU GENE AU PATIENT
US20110172308A1 (en) Antagonsim of PGF2a Receptor to Treat Hyertension Characterized by Activation of the Renin-Angiotensin-Aldosterone System
Kugathasan The Protective Role of the Angiopoetin-1-Tie2 System in Transgenic Models of Pulmonary Arterial Hypertension

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150723